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Abstract
Background: The popularity of botanical products is on the rise in Europe, with consumers using them to complement their
diets or to maintain health, and products are taken in many different forms (e.g. teas, juices, herbal medicinal products,
plant food supplements (PFS)). However there is a scarcity of data on the usage of such products at European level.
Objective: To provide an overview of the characteristics and usage patterns of PFS consumers in six European countries.
Design: Data on PFS usage were collected in a cross-sectional, retrospective survey of PFS consumers using a bespoke
frequency of PFS usage questionnaire.
Subjects/setting: A total sample of 2359 adult PFS consumers from Finland, Germany, Italy, Romania, Spain and the United
Kingdom.
Data analyses: Descriptive analyses were conducted, with all data stratified by gender, age, and country. Absolute
frequencies, percentages and 95% confidence intervals are reported.
Results: Overall, an estimated 18.8% of screened survey respondents used at least one PFS. Characteristics of PFS consumers
included being older, well-educated, never having smoked and self-reporting health status as ‘‘good or very good’’. Across
countries, 491 different botanicals were identified in the PFS products used, with Ginkgo biloba (Ginkgo), Oenothera biennis
(Evening primrose) and Cynara scolymus (Artichoke) being most frequently reported; the most popular dose forms were
capsules and pills/tablets. Most consumers used one product and half of all users took single-botanical products. Some
results varied across countries.
Conclusions: The PlantLIBRA consumer survey is unique in reporting on usage patterns of PFS consumers in six European
countries. The survey highlights the complexity of measuring the intake of such products, particularly at pan-European level.
Incorporating measures of the intake of botanicals in national dietary surveys would provide much-needed data for
comprehensive risk and benefit assessments at the European level.
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Introduction
Botanicals and their derivatives/preparations are used through-
out Europe for health purposes, with increased usage in the
general population as well as among specific subgroups encom-
passing children and pregnant women or those suffering from
diseases such as cancer among others [1–4]. Botanicals are used in
many different types of products, including foods, (teas and juices),
food supplements such as plant food supplements (PFS), herbal
medicinal products (HMP), homeopathic products, cosmetics,
biocides etc [5]. These different product categories are regulated
by specific legislation, depending on the intended use of the
product.
The European Union (EU) Directive on Food Supplements
(2002/46/EC) defines dietary supplements (which include PFS) as
[6]:
‘‘…foodstuffs the purpose of which is to supplement the normal
diet and which are concentrated sources of nutrients or other
substances with a nutritional or physiological effect, alone or in
combination, marketed in dose form, namely forms such as
capsules, pastilles, tablets, pills and other similar forms, sachets of
powder, ampoules of liquids, drop dispensing bottles and other
similar forms of liquids and powders designed to be taken in
measured small quantities’’.
The marketing of a product as a PFS however, depends on
national legislation, which differs widely across Member States.
Countries vary in the extent to which products are regulated, as
well as in the process of regulatory control. Some countries have
regulated the use of botanicals in detail (including negative and
positive lists), some apply specific conditions of use, (including
maximum usage levels or warnings for the consumer), and in
others less specific requirements exist. An added complexity lies in
the application of the basic European ‘‘principle of mutual
recognition’’, whereby any product that is lawfully marketed in
one Member State can be sold in all 27 Member States [5].
Moreover, the same botanical may be used as a food
supplement and as a medicinal product, depending on the
intended use of the product and both food supplements and
medicinal products often share the same form of presentation
(powders, pills or tablets). Hence the legal status of products differs
from one country to another, resulting in a complex market
environment. This so-called borderline issue between PFS and
HMP is a major obstacle to the marketing of PFS in the European
Union [5].
Plant food supplement usage data at EU level are scarce with
reports providing PFS market data as opposed to data reported
directly by the consumer [7]. Surveys on the intake of botanicals
have been conducted primarily in the context of the intake of
dietary supplements in general [8] or as part of surveys of
complementary and alternative medicine (CAM) therapies [9],
and issues such as the legal distinction between HMP and PFS
have not been taken into account. A recent systematic review
evaluating the demographic characteristics and health status
factors associated with CAM use reported that the majority of
population based consumption studies had been conducted in the
USA (64% of the 110 identified studies), and of these, 13% were in
Europe, with the majority carried out in Scandinavia (7%) and the
United Kingdom (5%) [4]. Studies have been limited by the
heterogeneity of definitions used, study designs and objectives
making it difficult to compare results and to extrapolate
Table 1. Validation study results.
Variable Concordancea Milan Las Palmas de Gran Canaria
n % n %
Product used Yes 47 95.9 48 100.0
No 2 4.1 0 0.0
Dose form (pills, capsules, etc) Yes 45 91.8 47 97.9
No 4 8.2 1 2.1
Doses per day Yes 45 91.8 38 79.2
No 4 8.2 10 20.8
aConcordance between both methods: the PFS usage questionnaire and the 6-month usage diary.
doi:10.1371/journal.pone.0092265.t001
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conclusions. The ambiguity of categories such as ‘‘natural
medicine’’, ‘‘herbal remedies’’ or ‘‘herbal medicine’’ and what
constitutes ‘‘dietary supplements’’ makes it nearly impossible to
attain reliable estimates of the prevalence of PFS usage in Europe,
with only limited data available at national levels [9–11] but not at
the European level.
A study by the European Advisory Services (EAS) on ‘‘The use
of substances with nutritional or physiological effect other than
vitamins and minerals in food supplements’’ [7], provided
information on European market and regulation data, and
highlighted the need for obtaining PFS usage data in order to
plan, monitor and evaluate national and European policies, as in
other regions of the world. One such example is the United States
of America, where the Alternative Health/CAM supplement of
the National Health Interview Survey (NHIS) has been collecting
data on botanical dietary supplements for some years now [12–
14].
The European Food Safety Authority (EFSA) has recognised the
lack of data in the sector and has published a number of reports
addressing related issues, namely the recommendations for
reporting the use of supplements and medicines by adults in any
pan-European dietary survey or project [15], and the ‘‘Compen-
dium of botanicals reported to contain naturally occurring
substances of possible concern for human health’’, aimed to help
with the safety assessment of botanicals and botanical preparations
intended for use as food supplements [16].
The purpose of this paper is to describe the type and frequency
of PFS usage reported in a retrospective survey of consumers in six
European countries; in addition we present the most frequently
used botanical ingredients in these products. We also highlight the
issues associated with measuring usage of PFS in European
populations and make recommendations for future research.
Materials and Methods
Ethics statement
Before initiating the fieldwork, approval for the conduct of the
survey was obtained from four ethics committees: the Bioethics
Commission of the University of Barcelona, Spain; the Ethics
Committee of the University of Milano, Italy; the Ethical
Committee of the Faculty of Medicine - Transilvania University
of Brasov, Romania; and the Coordinating Ethics Committee,
Hospital District of Helsinki and Uusimaa, Finland. Approval of
the survey by these four ethics committees required submitting all
survey material to their members for evaluation. No ethical
approval for the survey was needed in Germany and the United
Kingdom.
To ensure harmonisation and standardisation of the fieldwork
and data collection across countries, a market research organiza-
tion, European Fieldwork Group (EFG) was subcontracted to
implement the survey. The survey was conducted by EFG in
strict accordance with the ICC/ESOMAR Code on Market and
Social Research. In all countries, informed consent was obtained
verbally from all respondents after reading the survey information
sheet. All data were recorded manually i.e. pen-and-paper.
Recruitment of survey participants occurred in the selected cities
in each country. Approximately the first 1000 individuals per
country were systematically selected for screening i.e. intercepting
1 in every 5 individuals passing by to ask him/her the initial
screening questions; subsequent screening selection was performed
on a convenience basis i.e. intercepting individuals in places where
consumers were likely to be found, such as herbal shops,
pharmacies etc. Eligible respondents who agreed to participate
were given an appointment at their home/workplace to complete
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the main survey. The appointments of those willing to participate
were later reconfirmed by phone.
The data were made anonymous when recorded electronically
i.e. the respondents’ contact details were not entered into the
survey database. Instead, the market research organization
assigned ID numbers to each respondent and provided PlantLI-
BRA partners only the database with the assigned ID numbers.
Definition of plant food supplements in the PlantLIBRA
PFS consumer survey
Although there is a legal definition of Food Supplements (EU
Directive (2002/46/EC) [6] under which PFS reside, for the
purposes of this research it was necessary to develop a specific
definition of PFS whose main characteristic is that they contain
botanical preparations as ingredients for food supplementation.
Botanical preparations are obtained by subjecting botanicals
(plants, algae, fungi or lichens) to treatments such as comminution,
extraction, distillation, squeezing, fractionation, purification,
concentration or fermentation. These include extracts, essential
oils, expressed juices, powders, etc.
Botanical preparations can be considered as nutrients or other
substances. Thus, the definition of PFS for the survey was as follows:
PFS are "foodstuffs the purpose of which is to supplement the
normal diet and which are concentrated sources of botanical
preparations that have nutritional or physiological effect, alone or
in combination with vitamins, minerals and other substances
which are not plant-based. PFS are marketed in dose form, such as
capsules, pastilles, tablets, pills and other similar forms, sachets of
powder, ampoules of liquids, drop dispensing bottles, and other
similar forms of liquids and powders designed to be taken in
measured small unit quantities’’.
Products that did not meet this definition, such as herbal
remedies and other medicinal products based on botanicals, and
those that did not meet the PFS definition in terms of dosage, such
as herbal teas or juices, were excluded.
Sample population and PFS consumer definition
A cross-sectional, 12-month retrospective survey was conducted
in 24 cities in six European countries -Finland, Germany, Italy,
Romania, Spain and the United Kingdom. An estimated sample
size of 2000 screened individuals per country was calculated in
order to obtain a final sample of approximately 400 consumers per
country (total N= 2400 approximately). Per country, gender and
age group quotas were set as follows: 300 adults (18 to 59 years)
and 100 older adults (60-and-over years), with 30–50% male and
50–70% female. All individuals were screened by means of a brief
questionnaire which recorded PFS usage in the preceding 12
months. Individuals were considered eligible for inclusion if they
were over 18 years old and met either of the following specified
criteria, intended to capture the different usage patterns of PFS
consumers:
1) They had taken at least 1 PFS in the last 12 months, in an
appropriate dose form at a minimum frequency of either:
a) 1 daily dose for at least 2 consecutive or non-consecutive
weeks, or
b) 1 or more doses per week for at least 3 consecutive weeks
or
c) 1 or more doses per week for at least 4 consecutive or
non-consecutive weeks
2) They had taken 2 or more different PFS, in an appropriate
dose form, at a minimum frequency of 1 or more doses per
T
a
b
le
5
.
P
la
n
tL
IB
R
A
’s
P
FS
co
n
su
m
e
r
su
rv
e
y
–
P
FS
u
sa
g
e
p
at
te
rn
s,
p
e
r
p
ro
d
u
ct
u
se
d
b
y
a
re
sp
o
n
d
e
n
t,
o
ve
ra
ll
an
d
b
y
g
e
n
d
e
r
an
d
ag
e
g
ro
u
p
.
G
e
n
d
e
r
A
g
e
g
ro
u
p
T
o
ta
l
(n
=
2
8
7
4
)
M
a
le
(n
=
1
3
5
8
)
F
e
m
a
le
(n
=
1
5
1
6
)
1
8
–
5
9
y
e
a
rs
(n
=
2
1
3
1
)
$
6
0
y
e
a
rs
(n
=
7
4
3
)
n
%
(9
5
%
C
I)
n
%
(9
5
%
C
I)
n
%
(9
5
%
C
I)
n
%
(9
5
%
C
I)
n
%
(9
5
%
C
I)
I
to
o
k
it
w
h
e
n
e
ve
r/
sp
o
ra
d
ic
al
ly
5
6
8
1
9
.8
(1
8
.3
–
2
1
.2
)
2
8
0
2
0
.6
(1
8
.5
–
2
2
.8
)
2
8
8
1
9
.0
(1
7
.0
–
2
1
.0
)
4
3
7
2
0
.5
(1
8
.8
–
2
2
.2
)
1
3
1
1
7
.6
(1
4
.9
–
2
0
.4
)
I
ta
ke
it
p
e
ri
o
d
ic
al
ly
,
d
u
ri
n
g
th
o
se
ti
m
e
s
o
n
ly
1
0
7
2
3
7
.3
(3
5
.5
–
3
9
.1
)
5
3
3
3
9
.3
(3
6
.7
–
4
1
.9
)
5
3
9
3
5
.6
(3
3
.1
–
3
8
.0
)
8
2
7
3
8
.8
(3
6
.7
–
4
0
.9
)
2
4
5
3
3
.0
(2
9
.6
–
3
6
.4
6
)
I
to
o
k
it
w
h
e
n
I
h
ad
a
fl
ar
e
u
p
/w
o
rs
e
n
in
g
o
f
co
n
d
it
io
n
6
3
8
2
2
.2
(2
0
.7
–
2
3
.7
)
2
7
8
2
0
.5
(1
8
.3
–
2
2
.6
)
3
6
0
2
3
.8
(2
1
.6
–
2
5
.9
)
4
5
1
2
1
.2
(1
9
.4
–
2
2
.9
)
1
8
7
2
5
.2
(2
2
.1
–
2
8
.3
)
O
th
e
r
re
as
o
n
5
1
2
1
7
.8
(1
6
.4
–
1
9
.2
)
2
2
4
1
6
.5
(1
4
.5
–
1
8
.5
)
2
8
8
1
9
.0
(1
7
.0
–
2
1
.0
)
3
5
3
1
6
.6
(1
5
.0
–
1
8
.1
)
1
5
9
2
1
.4
(1
8
.5
–
2
4
.4
)
N
o
t
su
re
8
4
2
.9
(2
.3
–
3
.5
)
4
3
3
.2
(2
.2
–
4
.1
)
4
1
2
.7
(1
.9
–
3
.5
)
6
3
3
.0
(2
.2
–
3
.7
)
2
1
2
.8
(1
.6
–
4
.0
)
Q
u
e
st
io
n
s
as
ke
d
.
D
u
ri
n
g
th
e
la
st
1
2
m
o
n
th
s,
in
w
h
at
m
o
n
th
s
h
av
e
yo
u
ta
ke
n
th
is
su
p
p
le
m
e
n
t?
(m
ar
k
al
l
th
at
ap
p
ly
).
P
o
ss
ib
le
re
sp
o
n
se
s:
Ja
n
,
Fe
b
,
M
ar
,A
p
r,
M
ay
,J
u
n
e
,
Ju
ly
,
A
u
g
,
Se
p
,
O
ct
,N
o
v,
D
e
c,
A
ll
ye
ar
ro
u
n
d
;
W
h
y
d
id
yo
u
d
e
ci
d
e
to
ta
ke
th
is
su
p
p
le
m
e
n
t
in
th
e
m
o
n
th
s
st
at
e
d
?
(o
n
e
an
sw
e
r
o
n
ly
).
P
o
ss
ib
le
re
sp
o
n
se
s:
I
to
o
k
it
w
h
e
n
e
ve
r/
sp
o
ra
d
ic
al
ly
;
I
ta
ke
it
p
e
ri
o
d
ic
al
ly
,
d
u
ri
n
g
th
o
se
ti
m
e
s
o
n
ly
;
W
h
e
n
I
h
ad
a
fl
ar
e
u
p
/w
o
rs
e
n
in
g
o
f
co
n
d
it
io
n
;
O
th
e
r
re
as
o
n
;
N
o
t
su
re
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
2
2
6
5
.t
0
0
5
Usage of Plant Food Supplements by European Adults
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e92265
week, with the sum of the usage period of the 2 or more
products being equal to at least 4 weeks.
Instruments and variables
A short screening questionnaire was used to identify consumers
who met the survey inclusion criteria; it consisted of six questions
which allowed interviewers to identify eligible consumers, based on
the product(s) used, the frequency and duration of use and the
dose form. Eligible consumers subsequently completed a more
detailed questionnaire on their PFS usage in the preceding 12
months, providing details of product/plant names, dosage forms,
frequency of use, reasons for use, adverse effects, places and
patterns of purchase and information sources on products. These
questions were asked for each of up to a maximum of 5 different
PFS used. In addition, respondents were asked to provide socio-
demographic data including age, gender, level of education and
employment status, as well as self-reported height and weight and
further health-related lifestyle information.
Survey administration and data collection
Fieldwork and data collection for the cross-sectional survey were
conducted by the international market research company EFG,
from May 2011 to September 2012. The duration of the fieldwork
ensured that any seasonal variability in usage of products was
captured. The survey protocols and instruments -training material,
information sheet, informed consent, screening and usage
questionnaires-, were initially developed in English by consensus
amongst the research team, and subsequently translated into the
respective languages in each of the survey countries. Pilot
interviews were conducted in each participating country to assess
the comprehension of the questions and to determine the time
required to complete the survey.
In each participating country, trained interviewers systemati-
cally screened approximately 1000 individuals during the first
three months of the survey, which allowed the estimation of the
prevalence rate. Subsequently, screening and recruitment were
conducted on a convenience basis. The recruited eligible
consumers were interviewed face-to-face and the more detailed
PFS usage questionnaire completed.
Data preparation and statistical analysis
All data from the completed surveys were entered into the
statistical package SPSS for Windows v. 18 (IBM Corporation,
Somers, NY, USA), which was also used for data analysis.
Following review of the completed interviews by the research
team in each country, a database with botanical composition data
for all PFS products reported was compiled for each country and
then merged into a single database. Potential product duplicates
between countries were not removed. Each product was coded for
its botanical ingredients in scientific, English and local names and
botanicals were coded after removing duplicates between coun-
tries. Additionally, each product was categorised as a single- or
multi-botanical product. To indicate the certainty of the matching
of products, a series of numerical codes were used, based on those
used in the National Health and Nutrition Examination Survey
2005–2006 [17]. Values ranged from 1–5, where ‘‘1’’ indicated an
exact match, ‘‘2’’ a probable match, ‘‘3’’ a reasonable match, ‘‘4’’
a default match and ‘‘5’’ no match. Only products with certainty
values 1 to 4 have been included in the analyses.
Respondent data were recorded in a separate database. A number
of variables were created and/or recoded to facilitate reporting and
analysis, including: 1) ‘‘education level’’, defined as low, medium,
and high; 2) ‘‘BMI’’, which was calculated from self-reported weight
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and height, and for whichWHO criteria [18] were used to categorise
individuals as underweight (BMI,18.5 kg/m2), normal weight
(BMI 18.5-,25 kg/m2), overweight (BMI 25-,30 kg/m2) and
obese (BMI $30 kg/m2); 3) ‘‘physical activity’’, calculated using
the short version of the IPAQ [19] and defined as low, moderate or
high.
Absolute frequencies and percentages for each of the variable
categories were used to describe the qualitative nominal/ordinal
and discrete quantitative survey data. In turn, all data have been
stratified by gender, age range and country - also using absolute
frequencies and percentages and 95% confidence intervals. When
describing the association between two qualitative variables
(nominal or ordinal), contingency tables were used. The contin-
uous quantitative variables (e.g. BMI, alcohol) were recoded into
categorical variables.
It is important to note that when reporting the main results of
the survey, the unit of analysis varies depending on the variables
used, i.e. for certain variables the unit is an individual respondent,
however, given the potential intake of multiple supplements by one
respondent, the unit of analysis may change to the supplement
level. Furthermore, all results presented in the tables represent the
analysis of raw data as opposed to data weighted by the population
size. Data were not weighted because of the study methodology
selected, whereby all country samples were very similar in size and
included only PFS consumers.
Validation study
In order to validate the PFS usage questionnaire, a validation
study was conducted in which the data collected using the survey
instrument were compared with a 30 to 180-day diary (used as the
gold standard). The study was conducted in two of the
PlantLIBRA consumer survey cities: Las Palmas de Gran Canaria
(Spain) and Milan (Italy), where 48 and 49 consumers respectively
were recruited using convenience sampling. The PFS usage
questionnaire was completed by the respondents at the beginning
and at the end of the 6-month period of the validation; during this
time the consumers also completed the usage diary. Data from the
last questionnaire and the diary were compared for concordance,
and results are shown in Table 1, indicating a good agreement for
product consumed, dose form and doses per day.
Results
Characteristics of the PFS consumer sample
A final sample of 2359 consumers (those eligible and willing to
participate) was recruited from 11783 screened individuals
(Table 2). Due to different legal frameworks (different distribution
of botanicals in food supplements and medicinal products), more
individuals had to be screened in Finland in order to recruit the
required 400 consumers. Table 2 also shows the sample used for
the estimation of the usage prevalence rate. The estimated
weighted overall PFS usage prevalence rate was 18.8% and per-
country rates were as follows: Finland 9.6%, Germany 16.9%,
Italy 22.7%, Romania 17.6%, Spain 18.0% and the United
Kingdom 19.1%.
Survey respondents were recruited to fixed quotas for age and
gender, which were achieved, with some differences within
countries (Table 3). In Finland the proportion of adults aged
50–59 years was significantly higher (26.2%), whilst the opposite
was true in Italy, where consumers in that age group constituted
only 13.0% of adults. Romania had a significantly higher number
of consumers in the youngest age group (30.5%), in contrast to
Spain and the United Kingdom, where this age group represented
only 9.5% and 9.0% of adult consumers, respectively. A
significantly higher proportion of female consumers were recruited
in Spain (56.7%) and in the United Kingdom marginally more
males were recruited (50.3%). Across all countries, more than half
of the participants (57.5%) were employed (Table 3), with the
percentages slightly lower in Finland (50.9%) and in the United
Kingdom (52.4%). The majority of participating consumers were
educated to medium level (Table 3).
Respondents were asked a number of questions regarding
health-related lifestyle factors (Table 4). Less than half of the
consumers had never smoked (46.6%), less than one quarter were
ex-smokers (23.1%) and less than one third were current smokers
(30.3%).
More than half of the total respondents (59.3%) had not
consumed alcohol or had consumed it less than once daily; more
than a tenth (12.6%) reported daily alcohol consumption.
The proportion of overweight and obese people in the survey
was 49.8% (Table 4). Some significant differences in levels of
physical activity were noted between countries. High levels of
activity were reported by 85.5% of Romanian respondents
compared to a value of 42.9% across all countries.
Most of the respondents (65.1%) reported not being regular
consumers of food supplements other than PFS in the preceding
12 months, except for Finland (Table 4). The proportion of non-
consumers varied from 20.7% in Finland to more than 80% in the
United Kingdom and Italy. By contrast, in Finland 76.3% of the
individuals were regular consumers of food supplements.
Over half of all respondents (59.5%) reported not having used
CAM therapies/treatments in the past year. This is particularly
the case in Italy (74.6%), Romania (80.8%) and the United
Kingdom (92.6%).
Three quarters of consumers reported their health status as very
good or good (75.5%), while 3.6% reported it as bad or very bad
and 21.0% as neither bad nor good (Table 4).
Between countries, more consumers reported their health status
as very good or good in Romania (81.3%) and in the United
Kingdom (81.1%) than in other countries; though conversely the
highest proportion reporting their health status as bad or very bad
was also in the United Kingdom (7.6%).
Table 7. PlantLIBRA’s PFS consumer survey – Characteristics of PFS reported by respondents.
Total Finland Germany Italy Romania Spain United Kingdom
Number of products 1288 213 190 289 196 284 116
Number of botanicals 491 196 191 222 219 218 47
Number of manufacturers 449 69 99 106 61 97 17
Maximum number of ingredients per product 46 23 46 20 39 30 8
doi:10.1371/journal.pone.0092265.t007
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PFS usage patterns
Overall, products are most often taken ‘‘periodically’’ (37.3%)
with respondents also reporting using PFS when experiencing a
‘‘flare up or worsening of a condition’’ (22.2%) (Table 5). Products
are also used on a more ‘‘sporadic basis’’ (19.8%) and on ‘‘other
non-specified occasions’’ (17.8%). Both men and women reported
taking products on a periodic basis (39.3%, 35.6%) and this was
also true for both age groups (Table 5). Periodic use was reported
significantly more often in Finland (46.2%), Germany (50.7%),
Italy (41.3%) and Romania (41.8%), but in Spain, ‘‘another
reason’’ was most reported (46.0%) and in the United Kingdom,
sporadic use (34.8%) was significantly higher than any other
reason as to when products were used (Table 6).
PFS products used
Respondents reported a total of 1288 products across the six
countries. At individual country level, the highest numbers of
different PFS were used in Italy (289) and Spain (284); in the
United Kingdom, the number of different PFS was approximately
half that of the other countries (Table 7). The number of different
botanical ingredients was 491, with the maximum number of
different botanicals contained in a single product being 46 and
present in a German product. The United Kingdom differed from
the other countries as the products reported contained a lower
number of botanical ingredients (maximum 8).
In terms of the number of products used, 83.7% of all
consumers reported taking one product in the preceding 12
months, with 12.3% taking two products and 4.0% using more
than two products (Table 8). Generally this pattern was similar for
both men and women and across the age groups, although those
over 60 did report a significantly higher use of two or more
products than those under 60 (19.5% vs. 15.2%) (Table 8). At
country level (Table 9), some significant differences were noted: in
Finland, the percentage of consumers using two or more products
was significantly higher than in all other countries (40.2%).
Overall 51.5% of consumers used a single-botanical product
and 32.3% used one multi-botanical product (Table 8). There
were no significant differences between males and females in this
usage pattern, but consumers aged over 60 used less multi-
botanical products than those aged 18–59 (27.7% and 33.8%
respectively) (Table 8). Overall, fewer consumers reported using
two or more single-botanical products (4.4%) and two or more
single- and multi-botanical products (11.9%) (Table 8).
There were some significant differences across countries in the
type of products consumed (Table 9). In the six countries, the
values for single-botanical products range from 84.5% (the United
Kingdom) to 20.5% (Finland). Usage of multi-botanical products
was reported in all countries, with the lowest proportion (7.1%)
reported in the United Kingdom (Table 9). The use of two or
more single-botanical products was low in all countries as was the
usage of two or more single- and multi-botanical products. Finland
was an exception to the latter, with 38.2% of respondents taking
multiple products (Table 9).
The most common dose forms used (Table 10) are capsules
(38.3%) and pills/tablets/lozenges (36.8%). No significant differ-
ence was observed in relation to gender or age (Table 10). Across
the six countries (Table 11), solid forms are generally most
popular, although capsules were used less frequently in Romania
(17.7%). Liquid forms were less common in the United Kingdom
(8.2%) and Germany (9.9%), but more common in Finland
(26.2%) and Italy (26.4%) (Table 11).
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Botanicals used
A total of 491 botanicals -used in at least one PFS- were
reported across the six participating countries. An overview of all
the reported botanicals -clustered by intervals of frequency of
intake (number of consumers ranging from 194 to 5)- is shown in
Table 12. Based on the survey results, the eleven most frequently
used botanicals (numbers of consumers ranging from 194 to 100)
in descending order are Ginkgo biloba (ginkgo), Oenothera biennis
(evening primrose), Cynara scolymus (artichoke), Panax ginseng
(ginseng), Aloe vera (aloe), Foeniculum vulgare (fennel), Valeriana
officinalis (valerian), Glycine max (soybean), Melissa officinalis (lemon
balm), Echinacea purpurea (echinacea) and Vaccinium myrtillus
(blueberry) (Table 12).
Table 13 shows the overall unweighted ranking of botanicals, 1–
40, according to the number of consumers, in decreasing order.
Table 13 also shows that when unweighted overall data are
stratified by gender, only slight differences between men and
women become evident and only Glycine max (soybean) was used
significantly more by women than by men (Table 13).
When the overall top-40 botanical data are stratified by age
groups, slight differences become evident. In the group of 18–59
year-olds, the most frequently used botanicals comply with the
overall data just differing in the ranking, with Oenothera biennis
(evening primrose) being the most frequently used botanical
(Table 13). In the group of 60+ year-old a stronger shift can be
observed (Table 13). Although Ginkgo biloba (ginkgo) is still the most
reported botanical -as in the overall ranking- other botanicals are
frequently used by that age group. Harpagophytum procumbens (devil’s
claw), Vaccinium myrtillus (blueberry) and Allium sativum (garlic) are
within the most frequently reported botanicals, whereas Glycine max
(soybean), Melissa officinalis (lemon balm) and Echinacea purpurea
(echinacea) do not appear in the top 10 ranking.
Cross-country differences emerge when considering the overall
top-40 botanicals more frequently present in PFS products in each
of the individual six countries (Table 14). In the Finnish sample,
products containing Glycine max (soybean) are the most frequently
used, followed by those containing Echinacea angustifolia and purpurea
(echinacea). German consumers reported Ginkgo biloba (ginkgo),
Cynara scolymus (artichoke) and Olea europea (olive) as the most
frequently used botanicals; whilst in Romania, Ginkgo biloba
(ginkgo) was also the ingredient most frequently indicated,
followed by Aloe vera (aloe) and Panax ginseng (ginseng). Amongst
Italian consumers, Aloe vera (aloe) was the most frequently used
botanical, followed by Foeniculum vulgare (fennel) and Valeriana
officinalis (valerian). In Spain, PFS containing Cynara scolymus
(artichoke) were the most frequently used products, followed by
those containing Valeriana officinalis (valerian) and Equisetum arvense
(horsetail). In the United Kingdom, Oenothera biennis (evening
primrose) was by far the most frequently reported botanical
ingredient, followed by Panax ginseng (ginseng) and Hypericum
perforatum (St. John’s wort). In addition, there is a great variation in
the ranking of consumed botanicals among countries.
Discussion
The present paper reports the findings from a European multi-
country survey of PFS consumers: the PlantLIBRA PFS consumer
survey. Data on the usage of PFS at the European level are
limited, confined in the main to commercial market data [7] as
opposed to consumer survey data, as evidenced in the recent
review by Bishop and Lewith (2010)[4], where only 13% of
population based consumption studies were in Europe. The
European Food Safety Authority (EFSA) has recognised the lack ofT
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data in the sector and has published a number of reports
addressing related issues [15–16].
To our knowledge this is the first survey of consumers of PFS
undertaken in Europe. In total 2359 consumers of PFS were
recruited in this cross-sectional retrospective survey. Across all
countries prevalence of usage is estimated at 18.8%. Vargas-
Murga and colleagues (2011)[9] highlighted that comparable data
at European level is difficult to identify when reviewing prevalence
data from a selected number of European studies, evaluating PFS
or CAM usage, with values ranging from 0.8% to 70%. All studies
were based on nationally representative samples but the definition
of use of supplements varied widely, in some cases being self-
defined by the participant and not distinguishing between PFS and
HMP. The use of dietary supplements in a European population
was measured in the European Prospective Investigation into
Cancer and Nutrition (EPIC) study [8]. Usage was measured by
completion of a standardised 24-hour dietary recall and included
all dietary supplements that met the EU Directive 2002/46/EC.
Results indicated significant differences in overall dietary supple-
ment use between countries with herbs/plant-based supplements
representing 8–17% of the products used across the ten countries.
The prevalence rate reported here can be compared to rates
from surveys conducted in the United States, where data on usage
of dietary supplements, including herbal supplements, is collected
more routinely. It is similar to the rate reported in the 2002 and
2007 National Health Interview Surveys (NHIS), 18.9% and
17.9% respectively [20]; higher than the rates of both the
Eisenberg’s survey [21] and the Slone survey [22], with 14%
and 12.1% respectively; and lower than the 2002 Health and Diet
Survey (42%) [23] or the 1999 Kaiser Permanent Medical Care
Program of Northern California (KPMCP), with a prevalence of
28.3% [24]. These differences in prevalence across studies may in
part be due to the distinct selected population samples, survey
methodologies (i.e. sampling methods, data collection techniques)
or definitions of usage, as well as possible variations in health
beliefs and health behaviour of the different populations of study
[9], [24].
Survey respondents were recruited to set quotas for both age
and gender to reflect characteristics previously reported for dietary
supplement users. Age and gender are significant determinants of
the consumption of dietary supplements in general and in
botanical products in particular. Previous studies on the use of
dietary supplements or other herbal-related use show a higher
consumption among women as compared to men [1], [17], [24–
28] and a higher consumption among older adults as compared to
younger adults [24], [29–32].
Table 10. PlantLIBRA’s PFS consumer survey – PFS dose forms used, per product used by a respondent, overall and by gender and
age group.
Dose forms Total Gender Age group
(n =2874) Male (n =1358) Female (n=1516) 18–59 years (n =2131) $60 years (n=743)
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Capsulesa 1101 38.3 (36.5–40.1) 522 38.4 (35.9–41.0) 579 38.2 (35.8–40.6) 844 39.6 (37.5–41.7) 257 34.6 (31.2–38.0)
Pills/tablets/lozenges 1057 36.8 (35.0–38.5) 498 36.7 (34.1–39.2) 559 36.9 (34.4–39.3) 765 35.9 (33.8–37.9) 292 39.3 (35.8–42.8)
Liquidb 513 17.9 (16.5–19.3) 238 17.5 (15.5–19.6) 275 18.1 (16.2–20.1) 374 17.6 (15.9–19.2) 139 18.7 (15.9–21.5)
Ampoules 104 3.6 (2.9–4.3) 53 3.9 (2.9–4.9) 51 3.4 (2.5–4.3) 75 3.5 (2.7–4.3) 29 3.9 (2.5–5.3)
Otherc 99 3.4 (2.8–4.1) 47 3.5 (2.5–4.4) 52 3.4 (2.5–4.4) 73 3.4 (2.7–4.2) 26 3.5 (2.2–4.8)
Question asked. And in which form do you usually take it? (mark the applicable form). Possible responses: Pills/tablets/lozenges; Softgel capsules/pearls; Hard capsules;
Liquid (extract/syrup/drops); Sachets/packets; Ampoules; Other (specify); Not sure.
aCapsules: suftgels/pearls/hard capsules.
bLiquid: extract/syrups/drups.
cOther: Puwders, Sachets/Packets, Bars and ‘‘Not sure’’.
doi:10.1371/journal.pone.0092265.t010
Table 11. PlantLIBRA’s PFS consumer survey – PFS dose forms, per product used by a respondent, by country.
Dose forms Finland (n =665) Germany (n =446) Italy (n=417) Romania (n=464) Spain (n =465)
United Kingdom
(n=417)
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Capsulesa 206 31.0 (27.5–34.5) 225 50.5 (45.8–55.1) 144 34.5 (30.0–39.1) 82 17.7 (14.2–21.2) 250 53.8 (49.2–58.3) 194 46.5 (41.7–51.3)
Pills/tablets/lozenges 261 39.3 (35.5–43.0) 154 34.5 (30.1–39.0) 126 30.2 (25.8–34.6) 234 50.4 (45.9–55.0) 98 21.1 (17.4–24.8) 184 44.1 (39.4–48.9)
Liquidb 174 26.2 (22.8–29.5) 44 9.9 (7.1–12.6) 110 26.4 (22.1–30.6) 82 17.7 (14.2-21.2) 69 14.8 (11.6–18.1) 34 8.2 (5.5–10.8)
Ampoules 0 - 0 - 13 3.1 (1.5–4.8) 47 10.1 (7.4–12.9) 44 9.5 (6.8–12.1) 0 –
Otherc 24 3.6 (2.2–5.0) 23 5.2 (3.1–7.2) 24 5.8 (3.5–8.0) 19 4.1 (2.3–5.9) 4 0.9 (0.1–1.7) 5 1.2 (0.2–2.2)
Question asked. And in which form do you usually take it? (mark the applicable form). Possible responses: Pills/tablets/lozenges; Softgel capsules/pearls; Hard capsules;
Liquid (extract/syrup/drops); Sachets/packets; Ampoules; Other (specify); Not sure.
aCapsules: softgels/pearls/hard capsules.
bLiquid: extract/syrups/drops.
cOther: Powders, Sachets/Packets, Bars and ‘‘Not sure’’.
doi:10.1371/journal.pone.0092265.t011
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Other characteristics of dietary supplements users that have
been reported previously in the literature include having higher
educational attainment and socioeconomic status [24], [33–34],
being less likely to smoke [10], [32], [35], being more physically
active [10], [29], [32]. Bailey et al. also reported a moderate
alcohol consumption (1 drink per day) among dietary supplement
users as compared to nonusers. In contrast, a study by Rovira et al.
in a southern European population found no differences in lifestyle
factors such as physical activity, smoking, and alcohol consump-
tion between dietary supplement users and non-users [36]. Our
survey population consists exclusively of PFS consumers, but their
responses to a series of questions on health-related lifestyle factors
reflect some of the characteristics mentioned above. The majority
of PFS consumers perceived their health status to be ‘‘very good or
good’’, reflecting results reported in a number of studies on dietary
supplement users [32] and CAM and dietary supplement users
[24], where the answer ‘‘very good or excellent’’ has been reported
for self-reported health status.
The survey results indicate that most consumers reported using
one PFS product in the preceding 12 months, with 12% using two
products and 4% using more than two. Individual country data
show that Finnish consumers use more than one product and PFS
with more than one botanical component, and the opposite is
observed in the United Kingdom, where about 90% of the
consumers use only one PFS and the products contain mostly only
one botanical. In the United States, recent studies have reported
that about half of the adults report using one or more dietary
supplements [32], [37]. One of these studies also found that over
half of dietary supplement consumers used a single-botanical
product and one third used one multi-botanical product [32].
Similar results were found in our survey across all countries i.e.
smaller numbers of consumers reported using two or more single-
botanical products (4.4%) and two or more single- and multi-
botanical products (11.9%).
A wide variety of botanicals (491) is used in PFS consumed by
the respondents in this survey. Overall raw data show that the
most frequently (n.100) used botanicals in descending order are
Ginkgo biloba (ginkgo), Oenothera biennis (evening primrose), Cynara
scolymus (artichoke), Panax ginseng (ginseng), Aloe vera, Foeniculum
vulgare (fennel), Valeriana officinalis (valeriana), Glycine max (soybean),
Melissa officinalis (lemon balm), Echinacea purpurea (echinacea) and
Vaccinium myrtillus (blueberry). These results reflect some commer-
cial data which reported that ginkgo followed by echinacea, garlic
and ginseng were the four most commercially important botanicals
in the combined markets of seventeen EC Member States. In this
data, echinacea and ginkgo were part of the composition of
products registered as medicines [7], [9], which were excluded
from our survey. Similarly, the US Food and Drug Administration
2002 Health and Diet Survey, also a 12-month retrospective study,
reported the same four herbs/botanicals/or other nonvitamin-
nonmineral dietary supplements being the most used by its adult
population – although in the following order: echinacea, garlic,
ginkgo and ginseng (the latter including tea) [23]. Schaffer et al.
also reported echinacea as the most consumed botanical in the
Californian 1999 KPMCP survey, followed by ginkgo [24].
Differences between countries are more evident; the top list of
botanicals contained in PFS for each single country complies little
with the ranking of the overall data. As mentioned earlier, data
were not weighted by country population size because of the study
methodology which included very similar country-sample sizes of
PFS consumers only, therefore caution is needed when drawing
conclusions from these results at the overall 6-country level.
Overall data merely describes the collected pooled data from all 6
countries. However, if the overall ranking data were to be
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weighted by the population size -for example the 1–5 ranking
data-, the positions of the botanicals would have been only slightly
altered, with Oenothera biennis (evening primrose) being the most
consumed one, followed by Cynara scolymus (artichoke) Ginkgo biloba
(ginkgo), Panax ginseng (ginseng) and Aloe vera (aloe).
The results of the survey highlight clear differences between
countries in terms of the botanicals used by consumers as PFS.
Table 13. PlantLIBRA’s PFS consumer survey – distribution of the overall top-40 botanicals’ reported consumption and the ranking
of these botanicals when stratified by gender and age group.
All consumers Gender Age group
Botanicals Male Female 18-59 years $60 years
Ranka n % (95% CI) Rankb n % (95% CI) Rankb n % (95% CI) Rankb n % (95% CI) Rankb n % (95% CI)
Ginkgo biloba 1 194 8.2 (7.1–9.3) 1 107 9.4 (7.7–11.0)3 87 7.1 (5.7–8.6) 2 135 7.7 (6.4–8.9) 1 59 9.9 (7.5–12.3)
Oenothera biennis 2 194 8.2 (7.1–9.3) 3 85 7.5 (5.9–8.9) 1 109 9.0 (7.4–10.5)1 145 8.2 (6.9–9.5) 2 49 8.2 (6.0–10.4)
Cynara scolymus 3 173 7.3 (6.3–8.4) 5 73 6.4 (5.0–7.8) 2 100 8.2 (6.7–9.7) 4 128 7.3 (6.1–8.4) 4 45 7.6 (5.4–9.6)
Panax ginseng 4 167 7.1 (6.0–8.1) 2 94 8.2 (6.6–9.8) 5 73 6.0 (4.7–7.3) 3 133 7.5 (6.3–8.7) 6 34 5.7 (3.9–7.5)
Aloe vera 5 145 6.2 (5.2–7.1) 4 80 7.0 (5.5–8.5) 7 65 5.3 (4.1–6.6) 5 99 5.6 (4.5–6.7) 3 46 7.7 (5.6–9.8)
Foeniculum vulgare ssp. 6 132 5.6 (4.7–6.5) 7 59 5.2 (3.9–6.4) 4 73 6.0 (4.7–7.3) 6 99 5.6 (4.5–6.7) 7 33 5.6 (3.7–7.3)
Valeriana officinalis 7 125 5.3 (4.4–6.2) 6 62 5.4 (4.1–6.7) 8 63 5.2 (3.9–6.4) 7 97 5.5 (4.4–6.5) 9 28 4.7 (3.0–6.4
Glycine max 8 103 4.4 (3.5–5.2) 24 34 3.0 (2.0–3.9) 6 69 5.7 (4.4–6.9) 10 81 4.6 (3.6–5.5) 14 22 3.7 (2.2–5.2)
Melissa officinalis 9 103 4.4 (3.5–5.2) 8 53 4.7 (3.4–5.8) 10 50 4.1 (3.0–5.2) 9 82 4.7 (3.7–5.6) 17 21 3.5 (2.1–5.0)
Echinacea purpurea 10 102 4.3 (3.5–5.1) 12 43 3.8 (2.7–4.8) 9 59 4.8 (3.6–6.0) 8 83 4.7 (3.7–5.7) 21 19 3.2 (1.8–4.6)
Vaccinium myrtillus 11 100 4.2 (3.4–5.1) 9 53 4.7 (3.4–5.8) 13 47 3.9 (2.8–4.9) 12 71 4.0 (3.1–4.9) 8 29 4.9 (3.1–6.6)
Pimpinella anisum 12 89 3.8 (3.0–4.5) 11 47 4.1 (3.0–5.2) 21 42 3.5 (2.4–4.4) 16 65 3.7 (2.8–4.5) 11 24 4.0 (2.5–5.6)
Zingiber officinale 13 89 3.8 (3.0–4.5) 10 53 4.7 (3.4–5.8) 29 36 3.0 (2.0–3.9) 15 66 3.7 (2.9–4.6) 13 23 3.9 (2.3–5.4)
Camellia sinensis 14 87 3.7 (2.9–4.5) 17 39 3.4 (2.4–4.4) 11 48 3.9 (2.9–5.0) 11 72 4.1 (3.2–5.0) 33 15 2.5 (1.3–3.7)
Vitis vinifera 15 87 3.7 (2.9–4.5) 16 41 3.6 (2.5–4.6) 15 46 3.8 (2.7–4.8) 13 71 4.0 (3.1–4.9) 32 16 2.7 (1.4–4.0)
Taraxacum officinale 16 80 3.4 (2.7–4.1) 21 36 3.2 (2.1–4.1) 17 44 3.6 (2.6–4.6) 17 65 3.7 (2.8–4.5) 34 15 2.5 (1.3–3.7)
Echinacea angustifolia 17 79 3.4 (2.6–4.1) 23 34 3.0 (2.0–3.9) 16 45 3.7 (2.6–4.7) 20 60 3.4 (2.6–4.2) 20 19 3.2 (1.8–4.6)
Passiflora incarnata 18 78 3.3 (2.6–4.0) 30 30 2.6 (1.7–3.5) 12 48 3.9 (2.9–5.0) 19 61 3.5 (2.6–4.3) 30 17 2.9 (1.5–4.2)
Linum usitatissimum 19 77 3.3 (2.6–4.0) 13 43 3.8 (2.7–4.8) 33 34 2.8 (1.9–3.7) 22 56 3.2 (2.4–4.0) 16 21 3.5 (2.1–5.0)
Equisetum arvense 20 76 3.2 (2.5–3.9) 19 37 3.2 (2.2–4.2) 23 39 3.2 (2.2–4.2) 23 55 3.1 (2.3–3.9) 15 21 3.5 (2.1–5.0)
Allium sativum 21 75 3.2 (2.5–3.9) 28 32 2.8 (1.9–3.7) 18 43 3.5 (2.5–4.5) 29 50 2.8 (2.1–3.6) 10 25 4.2 (2.6–5.8)
Harpagophytum procumbens 22 75 3.2 (2.5–3.9) 18 39 3.4 (2.4–4.4) 26 36 3.0 (2.0–3.9) 40 40 2.3 (1.6–2.9) 5 35 5.9 (4.0–7.7)
Olea europaea 23 75 3.2 (2.5–3.9) 27 33 2.9 (1.9–3.8) 20 42 3.5 (2.4–4.4) 24 55 3.1 (2.3–3.9) 19 20 3.4 (1.9–4.8)
Glycyrrhiza glabra 24 74 3.1 (2.4–3.8) 26 33 2.9 (1.9–3.8) 22 41 3.4 (2.4–4.4) 25 54 3.1 (2.3–3.8) 18 20 3.4 (1.9–4.8)
Mentha piperita 25 72 3.1 (2.4–3.8) 20 36 3.2 (2.1–4.1) 27 36 3.0 (2.0–3.9) 27 53 3.0 (2.2–3.8) 22 19 3.2 (1.8–4.6)
Paullinia cupana 26 72 3.1 (2.4–3.8) 14 43 3.8 (2.7–4.8) 38 29 2.4 (1.5–3.2) 14 66 3.7 (2.9–4.6) 74 6 1.0 (0.2–1.8)
Malpighia glabra 27 71 3.0 (2.3–3.7) 15 41 3.6 (2.5–4.6) 37 30 2.5 (1.6–3.3) 18 61 3.5 (2.6–4.3) 51 10 1.7 (0.7–2.7)
Oenothera spec 28 70 3.0 (2.3–3.7) 41 23 2.0 (1.2–2.8) 14 47 3.9 (2.8–4.9) 21 59 3.3 (2.5–4.2) 47 11 1.9 (0.8–2.9)
Silybum marianum 29 69 2.9 (2.2–3.6) 25 34 3.0 (2.0–3.9) 30 35 2.9 (1.9–3.8) 32 46 2.6 (1.9–3.3) 12 23 3.9 (2.3–5.4)
Matricaria chamomilla 30 67 2.8 (2.2–3.5) 34 29 2.5 (1.6–3.4) 25 38 3.1 (2.1–4.1) 26 54 3.1 (2.3–3.8) 38 13 2.2 (1.0–3.3)
Citrus limon 31 66 2.8 (2.1–3.5) 37 24 2.1 (1.3–2.9) 19 42 3.5 (2.4–4.4) 30 48 2.7 (2.0–3.5) 25 18 3.0 (1.7–4.4)
Urtica dioica 32 64 2.7 (2.1–3.4) 31 30 2.6 (1.7–3.5) 34 34 2.8 (1.9–3.7) 28 51 2.9 (2.1–3.7) 37 13 2.2 (1.0–3.3)
Thymus vulgaris 33 63 2.7 (2.0–3.3) 36 28 2.5 (1.6–3.3) 31 35 2.9 (1.9–3.8) 33 44 2.5 (1.8–3.2) 24 19 3.2 (1.8–4.6)
Salvia officinalis 34 61 2.6 (2.0–3.2) 32 22 1.9 (1.1–2.7) 35 39 3.2 (2.2–4.2) 34 43 2.4 (1.7–3.1) 29 18 3.0 (1.7–4.4)
Cassia senna 35 60 2.5 (1.9–3.2) 43 29 2.5 (1.6–3.4) 24 31 2.6 (1.7–3.4) 37 43 2.4 (1.7–3.1) 28 17 2.9 (1.5–4.2)
Rosmarinus officinalis 36 60 2.5 (1.9–3.2) 38 24 2.1 (1.3–2.9) 28 36 3.0 (2.0–3.9) 39 41 2.3 (1.6–3.0) 23 19 3.2 (1.8–4.6)
Carum carvi 37 59 2.5 (1.9–3.1) 22 35 3.1 (2.1–4.0) 43 24 2.0 (1.2–2.7) 31 46 2.6 (1.9–3.3) 36 13 2.2 (1.0–3.3)
Hypericum perforatum 38 59 2.5 (1.9–3.1) 29 31 2.7 (1.8–3.6) 39 28 2.3 (1.5–3.1) 35 43 2.4 (1.7–3.1) 31 16 2.7 (1.4–4.0)
Lavandula angustifolia 39 57 2.4 (1.8–3.0) 40 23 2.0 (1.2–2.8) 32 34 2.8 (1.9–3.7) 36 43 2.4 (1.7–3.1) 35 14 2.4 (1.1–3.5)
Ribes nigrum 40 53 2.3 (1.7–2.8) 42 22 1.9 (1.1–2.7) 36 31 2.6 (1.7–3.4) 38 41 2.3 (1.6–3.0) 41 12 2.0 (0.9–3.1)
aProducts ordered according to the consumer distribution of the overall top-40 used botanicals (unweighted ranking).
bRanks show the shifts of the botanicals in the position of the overall 1–40 unweighted ranking when stratified by gender and age group.
doi:10.1371/journal.pone.0092265.t013
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This may reflect the fact that the current legal and regulatory
framework for botanicals has a major influence on the nature of
the local PFS markets. The EU Directive 2002/46/EC does not
provide a clear definition of what is encompassed by the term
‘other substance with a nutritional or physiological effect’,
although it is generally accepted that botanicals and their extracts
fall into this category. Current legislation varies across Europe,
with significant differences in the botanical species permitted in
PFS. These issues were highlighted in a recent review of the
regulations applicable to PFS in the European Union by Silano et
al. [38]. They provide examples of the different national
approaches for the use of selected botanicals in food supplements
in the EU Member States.
To illustrate the above complexity, in Germany, food supple-
ments are regulated by the German Regulation on Food
Supplements [39] and the German Law on Food and Feed [40].
Positive lists are available for minerals and vitamins. Food
supplements have to be registered with the Federal Office of
Consumer Protection and Food Safety [41]. The BVL maintains a
list of plants which are either classified as a food or a medicinal
product, and which is neither considered complete nor legally
binding [41]. Data on the intake of PFS in Germany is limited
and, despite food supplement intake being recorded in recent
health and nutrition surveys [42–44], no specific data was
published on PFS intake. The results from the PlantLIBRA
consumer survey do not include Valeriana officinalis in the German
top list of botanicals used in PFS, whereas 1852 medicinal
products containing Valerian exist on the market [40]. The
absence of Valeriana officinalis in the German list of botanicals can
be explained by its dominant presence as a HMP in the German
market.
The results of this survey represent some of the first data on the
usage of PFS at European level, thus addressing the existing deficit
of such data by collecting retrospective data directly from
consumers in six European countries. The benefits of the data
collection instrument used in this study included that it was
relatively straightforward to administer, did not alter habitual
usage patterns and allowed the classification of individuals into
categories of usage. However, the results must be considered in the
light of their limitations. The sample population comprises
exclusively of PFS consumers, recruited to meet very specific
inclusion criteria and hence no comparisons can be made with the
general population. Future studies should seek to compare users
and non-users of PFS.
Further limitations relate to the retrospective nature of the data
being collected. In many cases respondents needed to rely on
memory to report usage of products in the preceding 12 months.
Where products are available for inspection at data collection,
there is a need for careful recording of product details to ensure
accurate coding. The lack of a comprehensive product database
containing reliable ingredient information meant a bespoke
database needed to be created. Future studies should seek to
collect prospective data. Prospective dietary intake surveys offer an
ideal opportunity to collect data on supplement use in conjunction
with data on food and beverages. Care needs to be taken to collect
sufficiently detailed information about ingredients and amounts
consumed. For example, in the US, the Alternative Health/CAM
supplement of the National Health Interview Survey (NHIS) is
part of an annual, nationally representative survey of US adults. It
contains data on adults’ use of 10 herbs most commonly taken to
treat a specific health condition in the preceding 12 months [13];
the survey has a separate section on dietary supplements and
distinguishes ‘‘natural herbs’’ from vitamins and minerals. The
authors would like to encourage researchers to implement future
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surveys/studies which are necessary to overcome the bottlenecks
in PFS risk and benefit assessments at the European level.
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